The End Tuberculosis Now Act of 2026 (H.R. 10223) is a bipartisan bill introduced in the U.S. House of Representatives on September 2, 2026, by Rep. Ami Bera and nine co-sponsors. The bill aims to enhance U.S. foreign assistance efforts to prevent, diagnose, treat, and ultimately eliminate tuberculosis (TB) worldwide. Key provisions include: 1) Revising the Foreign Assistance Act to prioritize TB eradication through active case finding, quality diagnosis and treatment for all forms of TB (including drug-resistant and latent TB), patient support, infection control in congregate settings, strengthening laboratory and health systems, research and development (including vaccines and new diagnostics), and public-private partnerships. 2) Establishing specific targets for 2027 through 2030, such as reducing TB incidence by 80% and mortality by 90% compared to 2015 levels, diagnosing and treating 90% of TB cases, achieving 90% treatment success rates, and providing preventive treatment to 30 million people. 3) Requiring annual reports to Congress on implementation progress and outcomes, including data on screening, diagnosis, treatment completion, and research gaps, with a Government Accountability Office evaluation due after four years. All reporting requirements expire on January 1, 2033.
Media coverage summary coming soon.
In the absence of specific media coverage, potential criticisms of the bill could include concerns about the allocation of U.S. resources to global health initiatives, especially if domestic health issues are perceived as underfunded. Skeptics might question the feasibility of the ambitious targets set for TB reduction and the effectiveness of the proposed strategies. Additionally, some may argue that the bill does not specify funding levels, which could lead to uncertainties about its implementation and impact.
The analysis of H.R. 10223, aimed at preventing, treating, and curing tuberculosis globally, reveals no direct industry overlaps between the bill's subject matter and the sponsor Ami Bera's top donor industries. Bera's largest donor industry is Health Professionals, contributing $720 million, which may suggest a vested interest in health-related legislation. However, since the bill specifically addresses tuberculosis on a global scale and does not appear to directly benefit any specific health industry or company, the risk of conflict is minimized. Additionally, the second top donor industry, Retired, with contributions of $225 million, does not present any relevant conflicts related to the bill's focus on infectious disease control.
Top industries funding Ami Bera, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
